Greenbrook TMS Inc
TSX:GTMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Greenbrook TMS Inc
TSX:GTMS
|
CA |
|
A
|
Algernon Pharmaceuticals Inc
CNSX:AGN
|
CA |
|
Renaissance United Ltd
SGX:I11
|
SG |
|
X
|
XL Fleet Corp
XBER:XLF
|
US |
|
Cofidur SA
PAR:ALCOF
|
FR |
|
L
|
Linkers Industries Ltd
NASDAQ:LNKS
|
MY |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
US |
|
Wellnex Life Ltd
ASX:WNX
|
AU |
|
Computer Engineering & Consulting Ltd
TSE:9692
|
JP |
|
Archrock Inc
NYSE:AROC
|
US |
|
T
|
Thor Medical ASA
OSE:TRMED
|
NO |
|
H
|
Hanil Cement Co Ltd
KRX:300720
|
KR |
|
A
|
Atlas Global Brands Inc
CNSX:ATL
|
CA |
|
Graphic Packaging Holding Co
NYSE:GPK
|
US |
|
I
|
InFocus Group Holdings Ltd
ASX:IFG
|
AU |
Greenbrook TMS Inc
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. The company is headquartered in Toronto, Ontario and currently employs 430 full-time employees. The company went IPO on 2018-10-03. The TMS therapy is a non-invasive therapy for the treatment of depressive disorder (MDD) and other mental health disorders. The TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. The firm's patient-focused, customer service model provides TMS therapy accessible to all patients through three business processes: Patient Inquiry; Patient Conversion; and Treatment Delivery. A course of TMS consists of 36 treatments and a course of treatment consist of an initial cortical mapping and motor threshold determination and treatment, daily treatment sessions and a subsequent motor threshold re-determination and treatment. The company operates through approximately 130 Company-operated treatment centers. The company operates across the States of North Carolina, South Carolina, Maryland, Delaware, Missouri, Illinois, and Ohio.
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. The company is headquartered in Toronto, Ontario and currently employs 430 full-time employees. The company went IPO on 2018-10-03. The TMS therapy is a non-invasive therapy for the treatment of depressive disorder (MDD) and other mental health disorders. The TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. The firm's patient-focused, customer service model provides TMS therapy accessible to all patients through three business processes: Patient Inquiry; Patient Conversion; and Treatment Delivery. A course of TMS consists of 36 treatments and a course of treatment consist of an initial cortical mapping and motor threshold determination and treatment, daily treatment sessions and a subsequent motor threshold re-determination and treatment. The company operates through approximately 130 Company-operated treatment centers. The company operates across the States of North Carolina, South Carolina, Maryland, Delaware, Missouri, Illinois, and Ohio.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
